Basis: Four-quarter free cash flow / FMP quote market capitalization × 100. Source: stored company filings and market data; unavailable inputs remain N/A.
The free cash flow yield is N/A as of 2026-10-06T14:12:36.936Z.
Calculation as of: 2026-10-06T14:12:36.936Z.
Quote observation: 2026-10-06T14:10:21.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
FREE CASH FLOW YIELD
N/A
Kailera Therapeutics, Inc.
Market Cap
$1.35B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.40B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.34B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.33B
Free Cash Flow Yield
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$1.43B
Free Cash Flow Yield
1.26%
TTM Avg
0.66%
3Y Avg
0.66%
5Y Avg
1.32%
Market Cap
$1.45B
Free Cash Flow Yield
N/A
TTM Avg
14.53%
3Y Avg
14.53%
5Y Avg
14.53%
Market Cap
$1.47B
Free Cash Flow Yield
10.34%
TTM Avg
10.16%
3Y Avg
6.41%
5Y Avg
5.78%
| NAME | MARKET CAP | FREE CASH FLOW YIELD | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | $1.35B | N/A | N/A | N/A | N/A |
| Inhibrx Biosciences Inc. (INBX)vs › | $1.40B | N/A | N/A | N/A | N/A |
| Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs › | $1.34B | N/A | N/A | N/A | N/A |
| Alpha Tau Medical Ltd (DRTS)vs › | $1.32B | N/A | N/A | N/A | N/A |
| ArriVent BioPharma, Inc. (AVBP)vs › | $1.33B | N/A | N/A | N/A | N/A |
| AnaptysBio, Inc. (ANAB)vs › | $1.43B | 1.26% | 0.66% | 0.66% | 1.32% |
| Maze Therapeutics, Inc. (MAZE)vs › | $1.45B | N/A | 14.53% | 14.53% | 14.53% |
| Braveheart Bio, Inc. (BRVE)vs › | $1.46B | N/A | N/A | N/A | N/A |
| Healthcare Services Group, Inc. (HCSG)vs › | $1.47B | 10.34% | 10.16% | 6.41% | 5.78% |
| GH Research PLC (GHRS)vs › | $1.49B | N/A | N/A | N/A | N/A |
FCF Yield
N/A
Earnings Yield
N/A
Dividend Yield
N/A
Formula: FCF Yield = (Free Cash Flow / Market Cap) × 100
How FCF Yield is used:
FCF vs earnings: Differences between FCF yield and earnings yield can reflect capital expenditures, working capital changes, and other non-cash accounting items.
FCF Yield measures free cash flow relative to market capitalization. It compares cash generation after capital expenditures with the equity value of the company.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
